744
Views
12
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

, , , , , & show all
Pages 113-116 | Received 05 Mar 2009, Accepted 08 Jun 2009, Published online: 26 Jan 2010

Figures & data

Figure 1. Patient 1: (A) Severe purulent perforating bacterial folliculitis, with an atypical distribution as compared to the acneiform eruption seen in patients with an EGFR-inhibitor (left panel). (B) Recovery of acneiform eruptions after treatment with oral minocyclin 100 mg once daily (mid panel). (C) Histopathology of one of the lesions, showing an acanthotic epidermis with diffuse hyperkeratosis, a enlarged ruptured follicle with a massive influx of an inflammatory infiltrate mainly consisting of neutrophils. (Magnification 100′)

Figure 1. Patient 1: (A) Severe purulent perforating bacterial folliculitis, with an atypical distribution as compared to the acneiform eruption seen in patients with an EGFR-inhibitor (left panel). (B) Recovery of acneiform eruptions after treatment with oral minocyclin 100 mg once daily (mid panel). (C) Histopathology of one of the lesions, showing an acanthotic epidermis with diffuse hyperkeratosis, a enlarged ruptured follicle with a massive influx of an inflammatory infiltrate mainly consisting of neutrophils. (Magnification 100′)

Figure 2. Patient 3: Exacerbation of sharply demarcated erythematosquamous plaques and many pin-point psoriatic papules, designated as psoriasis.

Figure 2. Patient 3: Exacerbation of sharply demarcated erythematosquamous plaques and many pin-point psoriatic papules, designated as psoriasis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.